• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    What's Going On With OTR Acquisition Stock Today?

    5/18/22 11:09:13 AM ET
    $OTRA
    Get the next $OTRA alert in real time by email

    OTR Acquisition Corp (NASDAQ:OTRA) shares are trading higher Wednesday after the company filed a Form 8-K with the U.S. Securities and Exchange Commision. The move appears to be related to the high number of investors who opted for redemptions.

    According to the filing, holders of an aggregate of 9,769,363 shares of the company's stock have redeemed their shares in connection with the proposed business combination with Comera Life Sciences.

    There were 10,447,350 shares in total before redemptions. Only 677,987 shares were subject to redemption but not redeemed.

    Special purpose acquisition companies, or SPACs, often have redemption rights, which give investors the right to sell their shares back to the acquisition company for net asset value.

    The redemption of SPAC shares reduces the amount of outstanding shares which also leads to a decline in the amount of shares available to short. As a result, high redemption rates can often induce short squeezes. 

    OTR Acquisition expects the business combination to occur on or before May 19.

    See Also: 'We Faced Unexpectedly High Costs': Why Target Shares Are Falling Today

    OTR Price Action: OTR Acquisition shares were up 6.92% at $10.98 at time of publication.

    Photo: Lorenzo Cafaro from Pixabay.

    Get the next $OTRA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $OTRA

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $OTRA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Comera Life Sciences Debuts as Publicly Traded Company Focused on Transforming Biologics

    – Business combination transaction with OTR Acquisition Corp., a special purpose acquisition company, completed – – Combined company Comera Life Sciences Holdings, Inc. will be listed on the Nasdaq Capital Market under ticker symbol "CMRA" – Comera Life Sciences Holdings, Inc. ("Comera" or the "Company"), which is developing a new generation of bio-innovative biologic medicines to improve patient access, safety, and convenience, today announced the completion of its business combination with OTR Acquisition Corp. (NASDAQ:OTRAU, OTRA and OTRAW))) (referred herein as "OTR"), a publicly traded special purpose acquisition company (SPAC). Comera Life Sciences Holdings, Inc., the resulting comb

    5/20/22 8:00:00 AM ET
    $OTRA
    $OTRAU
    Business Services
    Finance

    Comera Life Sciences Announces Research Collaboration with Top 10 Pharmaceutical Company to Develop Subcutaneous Formulation

    Comera Life Sciences, Inc. ("Comera" or the "Company"), which is developing a new generation of bio-innovative biologic medicines to improve patient access, safety, and convenience, today announced it has entered into a research collaboration with a top 10 global pharmaceutical company and developer of medicines across oncology, hematology and immunology and other therapeutic areas. Under the terms of the agreement, Comera will utilize its proprietary SQore™ formulation platform to develop a subcutaneous formulation of the partner's currently marketed medicine. "Our second announced collaboration this year is a critical milestone in our long-term strategy to partner with top-tier pharma c

    5/9/22 8:00:00 AM ET
    $OTRA

    Comera Life Sciences to Present at 18th Annual PEGS Boston Conference & Expo

    Comera Life Sciences, Inc., which is developing a new generation of bio-innovative biologic medicines to improve patient access, safety, and convenience, today announced that Robert P. Mahoney, Ph.D., Chief Scientific Officer, will present at the PEGS Boston Conference & Expo, being held May 2-6, 2022, in-person. Dr. Mahoney will discuss Comera's lead, patented caffeine-based excipient, which significantly reduced the viscosity of prominent monoclonal antibodies without affecting their stability or biologic activity in a recent peer-reviewed study.1 The presentation details are as follows: Title: Viscosity Reducing Excipients for Highly Concentrated Antibody Formulations Time: May 4, 202

    4/27/22 8:00:00 AM ET
    $OTRA

    $OTRA
    SEC Filings

    View All

    SEC Form 15-12B filed by OTR Acquisition Corp.

    15-12B - OTR Acquisition Corp. (0001821318) (Filer)

    5/31/22 8:00:30 AM ET
    $OTRA

    OTR Acquisition Corp. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control of Registrant, Leadership Update, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - OTR Acquisition Corp. (0001821318) (Filer)

    5/24/22 4:31:11 PM ET
    $OTRA

    SEC Form 25-NSE filed by OTR Acquisition Corp.

    25-NSE - OTR Acquisition Corp. (0001821318) (Subject)

    5/19/22 4:06:33 PM ET
    $OTRA

    $OTRA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4: Gray Glenn Evan converted options into 22,123 shares and disposed of 100,000 shares

    4 - OTR Acquisition Corp. (0001821318) (Issuer)

    5/20/22 4:37:26 PM ET
    $OTRA

    SEC Form 4: Otr Acquisition Sponsor Llc converted options into 1,305,918 shares and disposed of 1,305,918 shares

    4 - OTR Acquisition Corp. (0001821318) (Issuer)

    5/20/22 4:35:50 PM ET
    $OTRA

    SEC Form 4: Besner Nadav converted options into 5,000 shares and disposed of 5,000 shares

    4 - OTR Acquisition Corp. (0001821318) (Issuer)

    5/20/22 4:36:27 PM ET
    $OTRA

    $OTRA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by OTR Acquisition Corp. (Amendment)

    SC 13G/A - OTR Acquisition Corp. (0001821318) (Subject)

    1/24/23 9:57:09 AM ET
    $OTRA

    SEC Form SC 13G/A filed by OTR Acquisition Corp. (Amendment)

    SC 13G/A - OTR Acquisition Corp. (0001821318) (Subject)

    5/20/22 4:37:55 PM ET
    $OTRA

    SEC Form SC 13G/A filed by OTR Acquisition Corp. (Amendment)

    SC 13G/A - OTR Acquisition Corp. (0001821318) (Subject)

    5/10/22 4:19:44 PM ET
    $OTRA